Results 41 to 50 of about 3,002,254 (310)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation [PDF]

, 2014
A John Camm,1 Pierre Amarenco,2 Sylvia Haas,3 Susanne Hess,4 Paulus Kirchhof,5,6 Martin van Eickels,4 Alexander GG Turpie71Division of Clinical Sciences, St George's, University of London, London, UK; 2Department of Neurology and Stroke Center, Paris-
Hess, S, Camm, AJ, Amarenco, Pierre, Eickels MV, Turpie, AG, Hess, Susanne, Haas, S, Turpie, Alexander G G, Kirchhof, P, van Eickels, M, Haas, Sylvia, Kirchhof, Paulus; id_orcid, Amarenco, P, Camm AJ, Hess S, Camm, John, Amarenco P, Van Eickels, Martin, Turpie AGG, Kirchhof P, Haas S   +20 more
core   +1 more source

Consensus Standards and Recommendations for Developmental and Cognitive Surveillance, Screening, and Evaluation in Sickle Cell Disease: Executive Summary From the National Alliance of Sickle Cell Centers Neurocognitive Workgroup

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurodevelopmental and neurocognitive difficulties are prevalent among individuals with sickle cell disease and warrant prompt identification and support. This Special Report provides an executive summary of standards and recommendations for surveillance, screening, and evaluation for development and cognition across the lifespan developed by ...
Alyssa M. Schlenz, Donna Murdaugh, Andrew M. Heitzer, Jennifer N. Longoria, Wendy Santos‐Modesitt, Arianna Martin, Judy Cavazos, Jeff Schatz, Catherine R. Hoyt, Alison King, Eboni I. Lance, Steven Hardy, Marsha Treadwell   +12 more
wiley   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

The evidence-base for stroke education in care homes [PDF]

, 2008
<b>Summary.</b> <b>Research questions:</b> 1. What are registered care home nurses’ educational priorities regarding stroke care? 2. What are senior care home assistants’ educational priorities regarding stroke care? 3. How do
Smith, L.N., Weir, C.J., Craig, L.E., McAlpine, C.H.   +3 more
core   +1 more source

The therapeutic opportunities and pitfalls of using iron ion chelators to treat neurodegenerative diseases

FEBS Letters, EarlyView.
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Stroke in China: advances and challenges in epidemiology, prevention, and management.

Lancet Neurology, 2019
With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk ...
Simiao Wu, Bo Wu, Ming Liu, Zhengming Chen, China Stroke Study Collaboration   +4 more
semanticscholar   +1 more source

Guiding AlphaFold to predict how Munc13‐1 opens Syntaxin‐1

FEBS Open Bio, EarlyView.
The syntaxin‐1 Habc‐domain (orange), linker (pink) and SNARE motif (yellow) form a closed conformation that binds to Munc18‐1 (violet) and is opened by the Munc13‐1 MUN domain (cyan) to form the SNARE complex that triggers neurotransmitter release.
Madhurima Chattopadhyay, Junjie Xu, Josep Rizo   +2 more
wiley   +1 more source

B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial:a randomised, double-blind, parallel, placebo-controlled trial [PDF]

, 2010
Epidemiological studies suggest that raised plasma concentrations of total homocysteine might be a risk factor for major vascular events. Whether lowering total homocysteine with B vitamins prevents major vascular events in patients with previous stroke ...
Hankey, G.J., Jamrozik, K., Klijn, C.J., van Bockxmeer, F. M., Hill, M., Gelavis, A., Ferro, J., Lisheng, L., Wong, L., Uddin, W., Eikelboom, J. W., Tan, K., Divjak, I., Baker, R.I., de Freitas, G., Wong, M. C., Eikelboom, J.W., Navarro, J., Slivka, A., Tsiskaridze, A., Lees, K. R., Algra, A., Yi, Q., Ricci, S., Chen, C., Dennis, Martin, Hankey, G. J., Baker, R. I., ?, ?, Groppa, S., Hickling, S. C., Cheung, R., Gommans, J., Spence, J. D., Schmidt, R., Ranawaka, U., Vasikaran, S., et al.   +37 more
core   +1 more source